Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program

Stock Information for Larimar Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.